Endoscopic mucosal resection with circumferential mucosal incision of duodenal carcinoid tumors

Otaki, Yuzo; Homma, Kiyoaki; Nawata, Yoshitakata; Imaizumi, Kazuomi; Arai, Shigeru

doi:10.4253/wjge.v5.i4.197

Cited by 9 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, several guidelines recommend endoscopic resection, rather than significantly more invasive open surgery, for duodenal NETs ≤10 mm in diameter and confined to the submucosal layer, with no evidence of lymph node or distant metastasis on CT [4,5,27,28]. Various endoscopic resection methods, such as EMR, EMR-L, EMR-P, EMR-C, and ESD, have been reported in the treatment of duodenal NETs [7,[11][12][13][14][16][17][18]29,30]. However, there is no consensus regarding the preferred method of endoscopic resection.…”

Section: Discussionmentioning

confidence: 99%

“…According to the European Neuroendocrine Tumor Society guidelines, endoscopic resection is recommended for non-ampullary duodenal neuroendocrine tumors (NAD-NET) ≤10 mm in diameter and confined to the submucosal layer, without lymph node or distant metastasis [4,5]. Various methods of endoscopic resection, including endoscopic mucosal resection (EMR), EMR with ligation device (EMR-L), EMR with circumferential precutting (EMR-P), cap-assisted EMR (EMR-C), and endoscopic submucosal dissection (ESD), have been reported in previous studies [6][7][8][9][10][11][12][13][14][15][16][17][18]. However, there is no consensus regarding the preferred method of endoscopic resection for NAD-NET.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors

Nishio

Hirasawa

Ozeki

et al. 2020

aog

View full text Add to dashboard Cite

Background Endoscopic resection is recommended for non-ampullary duodenal neuroendocrine tumors (NAD-NETs) ≤10 mm in diameter and confined to the submucosal layer, without lymph node or distant metastasis. However, the efficacy and safety of endoscopic submucosal dissection (ESD) for NAD-NET remains unclear. The aim of this study was to assess the short-term efficacy and safety and the long-term outcomes of ESD for NAD-NET.Methods Eight patients with 8 NAD-NETs who underwent ESD between 2015 and 2018 were included. The indications for ESD were: i) tumor ≤10 mm in diameter; ii) NET G1; iii) confined to the submucosal layer; and iv) without lymph node or distant metastasis. We retrospectively assessed the short-and long-term outcomes and safety. ResultsThe median patient age was 69 (48-76) years. All tumors were located in the duodenal bulb and showed 0-Is morphology. The median size was 6.4 (3-9.3) mm. The rates of en bloc resection, histologically free horizontal and vertical margins, and curative resection were 100%, 88%, and 88%, respectively. Intraoperative and postoperative perforation each occurred in 13% of patients, all of whom were treated conservatively and avoided emergent surgery. Delayed bleeding was not observed. No local, lymph node or distant recurrence was observed during a median follow-up period of 34 (18.5-62.5) months. ConclusionsThe rates of en bloc and curative resection, and histologically free margins were sufficiently high. Although intraoperative and postoperative perforations occurred, emergency surgery was not needed. The results show that ESD is an efficacious and safe treatment for NAD-NET.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors

Nishio

Hirasawa

Ozeki

et al. 2020

aog

View full text Add to dashboard Cite

show abstract

“…Yokoyama et al beschreiben eine erfolgreiche Resektion von 4 größeren Bulbus-NET (bis 13 mm Durchmesser) mittels konventioneller EMR [206]. Otaki et al berichten über 5 erfolgreiche Resektionen mittels EMR-CMI; Neumann et al berichten eine erfolgreiche Resektion mittels EMR-L [207,208]. Für die ESD duodenaler NET liegen nur kleine Studien mit hier relevanten Komplikationsraten vor.…”

Section: Starke Empfehlung Starker Konsensunclassified

S2k-Leitlinie Neuroendokrine Tumore

Gastroenterologie¹,

Tumoren²,

e.V.³

et al. 2018

Z Gastroenterol

130

View full text Add to dashboard Cite

show abstract

“…EMR technique was successful and safe treatment options for most small D‐NETs [7]. This safety issue was confirmed by more and more recent case series reported in the literatures [8,9]. Moreover, the EUS plays an important and unique role in the case of D‐NETs in evaluating the depth of invasion of the duodenal wall and in assistance for initial treatment strategy made.…”

Section: Discussionmentioning

confidence: 86%

Metachronous duodenal neuroendocrine neoplasms after endoscopic mucosal resection

Wang

Liang

et al. 2017

Adv in Digestive Medicine

View full text Add to dashboard Cite

Summary Duodenal neuroendocrine tumors (D‐NETs) may or may not be associated with a functional clinical syndrome. The term D‐NETs includes all duodenal tumors with neuroendocrine features as determined by histological/ immunohistochemical methods including positivity for neuroendocrine cytosolic markers (neuron‐specific enolase, or secretory vesicle proteins (chromogranin A (CgA), synaptophysin)). More than 90% of all D‐NETs arise in the first and second part of the duodenum. Approximately 20% of D‐NETs occurs in the periampullary region. Most D‐NETs are asymptomatic and incidentally detected during upper gastrointestinal (GI) endoscopy examinations for symptoms unrelated to the carcinoid tumor. D‐NETs account for 2% ‐ 5% of GI neuroendocrine tumors, and usually present as solitary small lesions confined to the duodenal submucosa. Endoscopic treatment is generally recommended for D‐NETs less than 10 mm as it is associated with a low frequency of lymph node invasion and distant metastases. However, the report of metachronous or synchronous concurrence of D‐NETs is scarce. Herein, we present a case of metachronous duodenal neuroendocrine tumor status successfully treated by hybrid endoscopic submucosal dissection. Copyright © 2017, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society of Taiwan and Taiwan Association for the Study of the Liver.

show abstract

Endoscopic mucosal resection with circumferential mucosal incision of duodenal carcinoid tumors

Cited by 9 publications

References 18 publications

Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors

Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors

S2k-Leitlinie Neuroendokrine Tumore

Metachronous duodenal neuroendocrine neoplasms after endoscopic mucosal resection

Contact Info

Product

Resources

About